Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mosedipimod - Enzychem Lifesciences

Drug Profile

Mosedipimod - Enzychem Lifesciences

Alternative Names: EC-18; PLAG

Latest Information Update: 17 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enzychem Lifesciences Corporation
  • Developer Enzychem Lifesciences Corporation; Korea Research Institute of Bioscience and Biotechnology
  • Class Anti-infectives; Anti-inflammatories; Antineoplastics; Chemoprotectants; Esters; Glycerols; Hepatoprotectants; Palmitic acids; Radioprotectives; Small molecules
  • Mechanism of Action Cytokine stimulants; Natural killer cell stimulants; Neutrophil stimulants; Toll-like receptor 4 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neutropenia; Acute radiation syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Adult respiratory distress syndrome; Neutropenia; Stomatitis
  • Clinical Phase Unknown Acute radiation syndrome
  • Preclinical Bladder cancer; Gouty arthritis; Non-alcoholic steatohepatitis; Sepsis

Most Recent Events

  • 17 Aug 2020 US FDA accepts IND application for mosedipimod in Acute respiratory distress syndrome (Prevention) for review
  • 14 Aug 2020 Enzychem Lifesciences plans a phase II trial for Acute respiratory distress syndrome (ARDS) due to Covid-19 infections (Prevention) in USA (NCT04569227)
  • 13 Jul 2020 Phase-II clinical trials in Adult respiratory distress syndrome (Prevention) in South Korea (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top